Matinas BioPharma Holdings, Inc. Annual report pursuant to Section 13 and 15(d)

Subsequent Events (Details Narrative) - USD ($)				12 Months Ended
Subsequent Events (Details Narrative) - USD ($)	Jan. 19, 2020	Jan. 14, 2020	Mar. 19, 2019	Dec. 31, 2019	Dec. 31, 2018	Feb. 19, 2020
Net proceeds from public offering of common stock			$ 27,800,000	$ 30,103,306
Common stock, par value				$ 0.0001	$ 0.0001
Equity Sales Agreement [Member]
Proceeds from issuance of debt				$ 10,400,000
Subsequent Event [Member]
Net proceeds from public offering of common stock		$ 50,000,000
Subsequent Event [Member] \| Maximum [Member] \| Equity Sales Agreement [Member] \| Cantor Fitzgerald & Co. [Member]
Net proceeds from public offering of common stock	$ 30,000,000
Subsequent Event [Member] \| After Deducting Underwriting Discounts and Commissions [Member]
Net proceeds from public offering of common stock		46,700,000
Subsequent Event [Member] \| Common Stock [Member]
Net proceeds from public offering of common stock		$ 32,300,000
Purchase price		$ 1.55
Subsequent Event [Member] \| Common Stock [Member] \| Equity Sales Agreement [Member]
Common stock, par value						$ 0.0001
Subsequent Event [Member] \| Common Stock [Member] \| Maximum [Member]
Options to purchase an additional shares of common stock		4,800,000